LGM Pharma announced on Mar. 19 the second phase of its contract development and manufacturing organization (CDMO) growth strategy, committing an additional $9 million to expand its facilities in Rosenberg, Texas, and Colorado Springs, Colorado. This investment follows a previously announced $6 million expansion in Rosenberg in 2025, bringing the company’s total recent investment to $15 million.
The expansion aims to increase commercial capacity and research and development capabilities at both sites to meet growing demand for U.S.-based drug product manufacturing. The Texas facility will receive $4 million to expand commercial-scale manufacturing suites for suppositories, with a focus on women’s health products. The upgrades will also enhance R&D capabilities for various dosage forms including suppositories, solutions, suspensions, and semi-solids. Construction is already underway at the Rosenberg site, which will remain fully operational throughout the process.
In Colorado Springs, LGM Pharma plans to invest $5 million to expand commercial manufacturing capacity for niche oral solid dose products such as orally disintegrating tablets. The facility has served as the company’s center of excellence for oral solid dose development. The expansion is expected to be completed this year and is intended to support increasing demand for domestic pharmaceutical manufacturing.
Hamilton Lenox, Chief Commercial Officer of LGM Pharma, said the company’s previous upgrades in Rosenberg from Phase I—including enhanced track-and-trace serialization systems and increased production volumes—are now complete. “We are executing this next phase of expansion while keeping both facilities fully operational,” Lenox said. “Our teams are experienced in managing complex upgrades without sacrificing quality or disrupting customer supply, which remain our top operational priorities. Rather than overextending in a single phase, we are executing these enhancements incrementally to expand capabilities and capacity while ensuring operational continuity. This approach allows us to strengthen infrastructure, support customer growth, and scale in response to market demand.”
LGM Pharma supports programs through a global network of more than 220 pre-qualified active pharmaceutical ingredient manufacturers by combining global drug substance sourcing with expanded U.S.-based finished dose development and manufacturing.
The company encourages organizations developing new drug applications or managing branded or generic portfolios to explore its expanded services or meet with executives at DCAT Week later this month.
